Citi upgraded BioAge Labs (BIOA) to Buy from Neutral with a price target of $10, up from $5. The firm believes the company’s BGE-102 can become a “differentiated” NLRP3 inhibitor in treating obesity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA: